profit from every $100 of sales.
$0$100
Bioventus
$11.02+3.82% today
+47.9% in 1 year
1-year low $6.531-year high $15.26
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay $33.18 for every $1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Bioventus sold, what it kept, and what it did with the cash.
Sales went from $512 million in 2022 to $568 million in 2025, with $22.7 million of profit last year.
SalesProfit
Bioventus vs. similar companies
Bioventus grows in the middle of these 5 and is the most expensive for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Bioventus | 33.2× · Expensive | ||
 Boston Scientific | 22.0× · Fair price | ||
 Koninklijke Philips | 30.0× · Fair price | ||
 Steris | 31.9× · Expensive | ||
 Zimmer Biomet Holdings | 29.1× · Fair price |
AI analysis
An AI analyst reads Bioventus's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 512 | 512 | 573 | 568 | |
| 331 | 328 | 388 | 388 | |
| -35 | 2 | 23 | 56 | |
| -122 | -23 | 36 | 99 | |
| -159 | -156 | -36 | 23 | |
| -2.59 | -2.49 | -0.52 | 0.33 | |
| 64.6% | 64.1% | 67.7% | 68.3% | |
| -6.8% | 0.4% | 4.0% | 9.9% | |
| -31.0% | -30.5% | -6.3% | 4.0% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 1,373 | 811 | 728 | 684 |
| Cash | 30 | 37 | 42 | 51 |
| Total debt | 418 | 395 | 336 | 294 |
| Total liabilities | 960 | 590 | 542 | 455 |
| 325 | 174 | 148 | 184 | |
| 61 | 63 | 65 | 69 | |
| -18.8% | -11.2% | -2.2% | 8.6% | |
| -48.8% | -90.0% | -24.4% | 12.3% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -14 | 15 | 39 | 75 | |
| 1 | 7 | 1 | 3 | |
| -15 | 8 | 38 | 72 | |
| Dividends paid | 0 | – | – | – |
| – | – | – | – | |
| 18 | 3 | 13 | 13 |
Valuation
- 33.2×
- 14.7×
- –
- 3.8×
- 1.3×
- 10.5×
- 10.0×
- 9.6%
- 3.0%
- 0.0%
Profitability
- 68.3%
- 9.9%
- 4.0%
- 18.7%
- 11.8%
- -9.8%
- 16.3%
- 4.4%
- 12.2%
- 2.0%
Growth
- +3.5%
- –
- +89.0%
- –
- +10.0%
Financial health
- 2.4×
- 0.10
- 2.9%
- 2.6×
- 1.69
- 1.13
- 0.89
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 22%of 948
Top 48%of 871
Bottom 41%of 560
Bottom 23%of 868
Top 8%of 985
What analysts expect
- Average price target
- $13.00
- Range
- $13.00 – $13.00
- 1 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 6, 2026 | 0.15 | 0.09 | +66.7% |
| Mar 5, 2026 | 0.24 | 0.22 | +9.1% |
| Nov 4, 2025 | 0.15 | 0.22 | −30.2% |
| Aug 6, 2025 | 0.21 | 0.22 | −4.5% |
| May 6, 2025 | 0.08 | 0.06 | +33.3% |
| Mar 11, 2025 | 0.15 | 0.08 | +87.5% |
| Nov 5, 2024 | 0.06 | 0.06 | +0.0% |
| Aug 6, 2024 | 0.19 | 0.07 | +171.4% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
33No pass
Benjamin Graham
28No pass
Philip Fisher
30No pass
Peter Lynch
44No pass
Joel Greenblatt
27No pass
Charlie Munger
27No pass
Terry Smith
28No pass
Questions about Bioventus
Is Bioventus a good stock to buy?
A business with weak numbers, but the price is high. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Bioventus AI analysis
What does Bioventus do?
Bioventus Inc. a medical device company, focuses on developing and commercializing clinical treatments that engage and enhance the body's natural healing process in the United States and internationally. It is in Medical - Devices.
Does Bioventus pay a dividend?
No. Bioventus does not pay a dividend at the moment.
Is Bioventus stock halal?
No. Bioventus does not pass our halal screen: its debt is 39% of its market value, at or above the 33% limit. How we check
How has Bioventus stock done over the past year?
Up 47.9% over the past twelve months, to $11.02. It traded between $6.53 and $15.26 and is 27.8% below its high.
Who are Bioventus's competitors?
The largest listed companies in the same industry are Boston Scientific, Koninklijke Philips, Steris and Zimmer Biomet Holdings. The peers table on this page compares their profit, growth and price with Bioventus's.
Prices: daily closes to Nov 9, 2026. Fundamentals: company reports via invest-like data.